HIV Medications 2026: 9 Drug Classes, $0 Options & What’s Coming

Antiretroviral therapy has transformed HIV from a fatal diagnosis into a manageable chronic condition. Today, more than 30 individual drugs across nine mechanistic classes are FDA-approved — giving clinicians and patients a wide range of options suited to different resistance profiles, tolerability needs, co-infections, and lifestyle preferences.

This guide was compiled by SunnyPharma’s clinical team from DHHS guidelines, FDA prescribing data, and peer-reviewed trial results. It covers all nine HIV drug classes, recommended first-line regimens for 2026, long-acting injectables, PrEP options, drug resistance, when and why patients switch regimens, what these medications cost, and what is coming in 2027. If you have questions about your specific regimen, your HIV specialist is the right source of guidance.

The Nine Classes of HIV Medications

HIV medications block different steps in the viral replication cycle. Combination therapy — drugs from two or more classes — prevents the virus from developing resistance to any single mechanism. This is why HIV treatment always uses at least two active drugs.

Recommended HIV Treatment Regimens 2026 (DHHS Guidelines)

The U.S. Department of Health and Human Services (DHHS guidelines) recommend INSTI-based regimens for most treatment-naive adults. All preferred options below are once-daily.

How Clinicians Choose Your Regimen: What Patients Should Know

Most competitors list regimens without explaining how the selection actually happens. Here is what your clinician is evaluating — and the questions worth asking at your appointment.

The factors that determine your regimen

• Resistance test results: A genotypic resistance test at diagnosis identifies mutations that could reduce drug efficacy. This is done before starting ART and is critical for regimen selection.
• HLA-B*5701 status: A genetic marker that predicts abacavir hypersensitivity. Must be tested before any abacavir-containing regimen (Triumeq, Epzicom).
• Hepatitis B co-infection: Biktarvy and Truvada-based regimens contain emtricitabine and/or TAF/TDF, which are also active against hepatitis B. Dovato does not — stopping it in an HBV co-infected patient can cause severe hepatitis flares.
• Kidney function: TDF-based regimens require monitoring for nephrotoxicity. TAF has a significantly better renal safety profile. Patients with reduced kidney function should generally avoid TDF.
• Bone density: TDF is associated with modest reductions in bone mineral density. TAF and INSTI-based regimens have lower bone impact. Relevant for patients with osteoporosis risk.
• Weight: INSTIs combined with TAF are associated with greater weight gain than older regimens. Clinicians discuss this when weight is a health concern.
• Drug interactions: Several common medications affect ART. Antacids containing polyvalent cations (calcium, magnesium, aluminum, iron) can chelate bictegravir and dolutegravir if taken simultaneously. Rifampin (for TB) significantly reduces most INSTI levels. Always provide your full medication and supplement list.
• Pregnancy: Dolutegravir is the preferred INSTI in pregnancy. Bictegravir data in pregnancy is more limited. First-trimester neural tube defect risk with dolutegravir appears low based on updated data, but this is still discussed at counseling.
• Adherence preference: If daily pills are difficult, long-acting injectable options are now a real clinical pathway, not a last resort.

Questions to ask at your appointment

• What did my resistance test show, and does it affect my options?
• Do I need HLA-B*5701 testing before we decide?
• Do I have hepatitis B, and does that change the regimen?
• How will this interact with my other medications?
• What side effects are most likely in the first four weeks?
• How will we know the treatment is working, and how often will we check?
• Am I a candidate for long-acting injectables instead of daily pills?
• What assistance programs can reduce my out-of-pocket cost?

HIV Drug Resistance: What It Is and What Happens Next

Drug resistance is one of the most clinically significant challenges in HIV treatment — and one of the topics patients are least prepared for at diagnosis. Most patient-facing resources skip it entirely.

How resistance develops

HIV replicates rapidly and imprecisely, producing billions of viral copies daily with frequent mutations. Most mutations are harmless or reduce viral fitness. But some mutations reduce a drug’s ability to bind to its target, allowing virus with that mutation to replicate preferentially while other variants are suppressed. Consistent ART adherence prevents this — when drug levels stay high and continuous, no variant has a replication window. Missed doses create the opportunity.

Resistance testing: how it works

A genotypic resistance test sequences specific regions of HIV’s genome from a blood sample and identifies mutations associated with reduced drug susceptibility. Results are interpreted against a database of known resistance mutations (the Stanford HIV Drug Resistance Database is the standard reference). The report shows which drugs the patient’s virus is likely to respond to and which to avoid.

DHHS guidelines recommend resistance testing:

• At entry into HIV care, before starting ART
• If ART is started before resistance results are available, testing should still be done and results used to modify the regimen if needed
• Whenever there is virologic failure (detectable viral load on treatment)
• In pregnant people with HIV at entry into prenatal care

What transmitted resistance means

Transmitted drug resistance (TDR) is resistance acquired before a person ever takes ART — contracted from a partner whose virus already carried resistance mutations. In the US, approximately 15–20% of newly diagnosed patients have at least one transmitted resistance mutation. This is why baseline resistance testing is standard of care, not optional.

Switching HIV Medications: When, Why, and How

Switching regimens is common and often clinically appropriate. It does not mean treatment is failing. Understanding the reasons for switching helps patients participate in the decision.

Common reasons to switch

• Virologic failure: A confirmed detectable viral load on treatment. The threshold that triggers investigation is typically HIV RNA >200 copies/mL on two consecutive measurements. Switching without a new resistance test risks adding drugs the virus is already resistant to.
• Simplification: Moving from a multi-tablet regimen to a single-tablet regimen, or from daily pills to a long-acting injectable. Simplification switches are common and well-studied.
• Side effects: Weight gain, insomnia, or gastrointestinal intolerance are legitimate and common reasons to switch within a class. Clinicians can often move to a different regimen with a better tolerability profile without compromising efficacy.
• Drug interactions: A new medication that significantly alters ART drug levels may require a regimen change.
• Pregnancy: Some ART components require substitution during pregnancy based on updated safety data.
• Preference for injectable therapy: Virologically suppressed patients who are adherent on their current oral regimen may switch to Cabenuva if they prefer not to take daily pills.

What the switch process looks like

A clinician-guided switch typically involves: confirming the reason for switching, ordering a resistance test if virologic failure is involved, reviewing the full treatment history, selecting a new regimen with at least two fully active drugs, and scheduling a follow-up viral load at 4 weeks to confirm suppression is maintained. Patients switching for simplification or tolerability reasons (not virologic failure) generally do not need a resistance test.

Long-Acting Injectable HIV Medications

Long-acting injectables replace daily pills with periodic clinic visits. They are now an established option for both HIV treatment and prevention — not experimental, not last-resort.

For HIV Treatment

• Cabenuva (cabotegravir + rilpivirine): Monthly or every-two-month intramuscular injection. Approved for adults who are virologically suppressed on a stable oral regimen. Requires a one-month oral lead-in with the individual components. The first complete injectable ART regimen. Not suitable for patients with rilpivirine resistance mutations or certain drug interactions.
• Sunlenca (lenacapavir): Subcutaneous injection every six months, combined with an optimized oral background regimen. Approved for adults with multi-drug resistant HIV who have limited options. Also in development as part of an all-injectable combination.

For PrEP (HIV Prevention)

• Apretude (cabotegravir): Every two months by intramuscular injection. Approved for HIV-negative adults and adolescents at risk. Shown to be more effective than daily oral TDF/FTC in HPTN 083 and HPTN 084 trials.
• Yeztugo (lenacapavir): Every six months by subcutaneous injection. Approved 2025. Demonstrated over 99% efficacy in PURPOSE 1 (cisgender women, sub-Saharan Africa) and PURPOSE 2 (MSM and transgender/gender-diverse individuals, multiple countries). The first twice-yearly PrEP option.

PrEP Options in 2026

Pre-Exposure Prophylaxis (PrEP) is for HIV-negative individuals at risk of HIV. It prevents infection — it does not treat it. Current FDA-approved options and guideline-recommended approaches include:

On-demand PrEP (2-1-1): what no other resource explains clearly

On-demand PrEP — also called event-driven PrEP or 2-1-1 — is a dosing strategy that centers pill-taking around specific sexual encounters rather than a daily schedule. It is supported by the IPERGAY trial and recommended by DHHS and WHO for cisgender MSM.

The protocol: Take two tablets of TDF/FTC 2 to 24 hours before anticipated sex. Take one tablet 24 hours after the first dose. Take one tablet 48 hours after the first dose. If sex continues on additional days, take one tablet daily until two days after the last sexual contact.

Who it is and is not for: On-demand PrEP is only studied and recommended for cisgender men who have sex with men. It is not appropriate for people who have receptive vaginal sex, people with hepatitis B, or for cabotegravir-based PrEP. Daily dosing or injectable PrEP are the appropriate options for those groups.

Side Effects of HIV Medications

Modern INSTI-based regimens are well tolerated compared to older HIV drugs. Most patients starting Biktarvy or a dolutegravir-based regimen experience few significant side effects. What patients most often want to know is when to be concerned and when to wait.

Early side effects (first 2–4 weeks) — usually resolve

• Nausea, headache, and fatigue are common and typically resolve within two to four weeks
• Insomnia or vivid dreams, particularly with dolutegravir-based regimens, often improve with time or by taking the dose in the morning rather than at night
• Diarrhea or loose stools, usually mild and transient

Longer-term monitoring

• Weight gain: Associated with INSTI + TAF combinations, particularly dolutegravir and bictegravir. Appears to be more pronounced in women and Black patients in clinical data. Mechanisms are not fully understood. Clinicians monitor weight and discuss lifestyle factors.
• Kidney function: TDF-based regimens require periodic kidney monitoring. TAF has a significantly better renal safety profile and is preferred for patients with existing kidney disease.
• Bone density: TDF is associated with modest reductions in bone mineral density. TAF and INSTI-based regimens have lower bone impact. DEXA scans are recommended for patients with osteoporosis risk factors.
• Lipids and metabolic markers: Lipid profiles and blood glucose should be checked periodically. Some protease inhibitors and older NNRTIs have more pronounced effects on cholesterol.
• Neuropsychiatric effects: Efavirenz (now less commonly used) is associated with dizziness, vivid dreams, and mood changes. Dolutegravir is associated with insomnia in a subset of patients. These are manageable with timing adjustments or regimen changes.

What HIV Medications Cost — and What Patients Actually Pay

HIV drug list prices in the US are among the highest in the world. But list price and patient cost are two completely different numbers. Most patients pay significantly less — or nothing — through insurance and assistance programs.

The key cost pathways for HIV medications:

• Commercial insurance + manufacturer copay card: Most commercially insured patients pay $0–$5/month. Gilead’s Advancing Access copay card (1-800-226-2056) covers up to $7,200/year. ViiV Healthcare offers a similar program for Cabenuva and Dovato.
• Medicare Part D + Extra Help: Patients with the Low-Income Subsidy typically pay $4–$9/month. Manufacturer copay cards cannot be used with Medicare — nonprofit foundations (PAF, PAN, HealthWell) fill this gap.
• Medicaid: HIV medications are covered in all state Medicaid programs, typically with minimal or no copay.
• Ryan White / ADAP: The AIDS Drug Assistance Program provides free HIV medications to uninsured and underinsured patients. All 50 states participate. Find your state program at nastad.org/adap-watch.
• Manufacturer patient assistance: Gilead’s PAP provides free Biktarvy to qualifying uninsured patients with income up to ~500% of the federal poverty level. Call 1-800-226-2056.
• 340B pricing: Ryan White clinics and FQHCs may dispense HIV medications at significantly reduced cost through the 340B program. Ask your clinic if they participate.

Undetectable = Untransmittable (U=U)

People living with HIV who maintain an undetectable viral load through consistent ART have effectively zero risk of sexually transmitting HIV to a partner. This is not a caveat-laden probability reduction — it is zero observed transmissions across more than 75,000 acts of sex without condoms in the PARTNER and PARTNER2 studies combined.

U=U is confirmed by HPTN 052, PARTNER, PARTNER2, and Opposites Attract, and endorsed by the NIH, CDC, UNAIDS, and over 1,100 organizations in 105 countries. Achieving and maintaining undetectable status requires consistent ART adherence and regular viral load monitoring, typically every 3–6 months.

New HIV Drugs in Development: 2026–2027 Pipeline

HIV drug development is advancing rapidly toward longer-acting options, weekly oral alternatives, and improved resistance coverage. These are the most clinically significant developments.

• Bictegravir / lenacapavir single-tablet regimen (Gilead): A daily oral combination combining a high-barrier INSTI with a capsid inhibitor. ARTISTRY-1 (switch from complex multi-tablet) and ARTISTRY-2 (switch from Biktarvy) both showed maintained viral suppression non-inferior to existing regimens. FDA submission is pending. Potential 2027 approval. This combination would offer activity against INSTI-resistant virus due to lenacapavir’s distinct mechanism.
• Islatravir / lenacapavir once-weekly (Merck + Gilead): A once-weekly single-tablet regimen combining a novel NRTTI with a capsid inhibitor. Phase 3 ISLEND-1 and ISLEND-2 trials are ongoing. Phase 2 data showed maintained suppression at 96 weeks in adults switching from daily Biktarvy.
• Islatravir / doravirine daily (Merck): A daily two-drug regimen with a novel mechanism pairing. Phase 3 data showed maintained suppression at 48 weeks in switch studies, and efficacy in treatment-naive patients. A distinct option from current INSTI-based standards.
• Ulonivirine (Merck): A next-generation NNRTI in development as a once-weekly partner for islatravir. Designed to address the low-barrier-to-resistance limitation of older NNRTIs.
• VH-184 (ViiV Healthcare): A third-generation INSTI with demonstrated activity against dolutegravir- and bictegravir-resistant HIV. Phase 1 data support long-acting injectable formulation development.
• Broadly neutralizing antibodies (bNAbs): Bispecific and trispecific bNAb combinations targeting multiple conserved HIV epitopes are in clinical trials as both treatment and prevention strategies, with potential as functional cure approaches.

Biktarvy: In-Depth Guides

Biktarvy is the most prescribed HIV regimen in the United States. Our cluster covers every question patients and caregivers ask about it.

Frequently Asked Questions